Gilead's Kite unit touts survival benefit of Yescarta in large B-cell lymphoma
ElementalImaging


Kite, a unit of Gilead Sciences (NASDAQ:GILD), said that phase 3 data on its CAR-T therapy Yescarta demonstrated a significant improvement in overall survival compared to standard treatment in those with large B-cell lymphoma.
The ZUMA-7 study examined Yescarta (axicabtagene ciloleucel) in this population as a first-line therapy. The overall survival measure is based on completion of initial therapy within 12 months.

Overall survival was identified as a prespecified key secondary endpoint. ZUMA-7's primary endpoint was event-free survival, a measure that was used to support the biologic's approval in 2022.
The new analysis showed that Yescarta led to 2.5-fold increase in patients who were alive at two years and did not experience cancer progression or require the need for additional treatment.
Read why Seeking Alpha contributor Sanjay Chandiramani argues that Gilead (GILD) is a buy.